Treatment Strategies For Depression Research Articles

Efficacy of agomelatine on sleep disorders and lateral habenula neuronal activity in chronic restraint stress depression model mice.

Sleep disorders (SD) are one of the common manifestations of depression patients. This article aimed to explore the effect of Agomelatine (Ago) on SD in chronic restraint stress (CRS) depression model mice and its effect on the activity of neurons in the lateral habenula (LHb). 30 C57BL/6J mice were divided into normal (C57BL/6J) group, CRS group, and Ago group. CRS experiment was used to establish the depression model, and Ago was used to treat CRS mice. Based on behavioral tests in mice and electrophysiology record, SD and LHb neuron activity were assessed. The expression levels of brain-derived neurotrophic factor (BDNF) and nuclear phosphoprotein (c-Fos) in LHb were detected by Western blot (WB). As against the CRS group, the Ago group had a reduction in the immobility time during forced swimming training and an increase in the preference for sucrose in the sucrose preference test; The expression levels of c-Fos and BDNF proteins in the LHb neurons of the Ago group mice were lower than those in the CRS group (P < 0.05), and the values approached the levels of the normal control group. In both dark and light environments, the rapid eye movement (REM) sleep duration of the CRS group mice was significantly longer than that of the normal control group (P < 0.05). It was concluded that Ago may intervene in the depressive-like behavior and overall sleep patterns of CRS depression model mice by regulating the activity of LHb neurons and inhibiting the neuroinflammatory process. This provides a potential drug target for the development of new treatment strategies for depression.

Antioxidant Carbon Dots Nanozymes Alleviate Stress-induced Depression by Modulating Gut Microbiota.

Depression is a debilitating mental illness that severely threatens millions of individuals and public health. Because of the multifactorial etiologies, there is currently no cure for depression; thus, it is urgently imperative to find alternative antidepressants and strategies. Growing evidence underscores the prominent role of oxidative stress as key pathological hallmarks of depression, making oxidative stress a potential therapeutic target. In this study, we report a N-doped carbon dot nanozyme (CDzyme) with excellent antioxidant capacity for treating depression by remodeling redox homeostasis and gut microbiota. The CDzymes prepared via microwave-assisted fast polymerization of histidine and glucose exhibit superior biocompatibility. Benefiting from the unique structure, CDzymes can provide abundant electrons, hydrogen atoms, and protons for reducing reactions, as well as catalytic sites to mimic redox enzymes. These mechanisms collaborating endow CDzymes with broad-spectrum antioxidant capacity to scavenge reactive oxygen and nitrogen species (•OH, O2-•, H2O2, ONOO-), and oxygen/nitrogen centered free radicals. A depression animal model was established by chronic unpredictable mild stress (CUMS) to evaluate the therapeutic efficacy of CDzymes from the behavioral, physiological, and biochemical index and intestinal flora assessments. CDzymes can remarkably improve depression-like behaviors and key neurotransmitters produced in hippocampus tissues and restore the gut microbiota compositions and the amino acid metabolic functions, proving the potential in treating depression through the intestinal-brain axis system. This study will facilitate the development of intestinal flora dysbiosis nanomedicines and treatment strategies for depression and other oxidative stress related multifactorial diseases.

Depression Part 2: Treatment.

Depression treatment strategies are within the scope of pediatric practice and among the competencies recommended by the Academy of Pediatrics and The American Board of Pediatrics. Treatments that may be provided through collaborative care include nonpharmacologic therapies such as psychosocial treatments and evidence-based psychotherapies, and pharmacotherapy and monitoring processes for depression. Abundant support and guidance are available to pediatricians in depression care, including mental health consultation and online materials.

Rasd2 regulates depression-like behaviors via DRD2 neurons in the prelimbic cortex afferent to nucleus accumbens core circuit.

Depressive symptoms, such as anhedonia, decreased social interaction, and lack of motivation, implicate brain reward systems in the pathophysiology of depression. Exposure to chronic stress impairs the function of brain reward circuits and is well-known to be involved in the etiology of depression. A transcriptomic analysis found that stress alters the expression of Rasd2 in mice prefrontal cortex (PFC). Similarly, in our previous study, acute fasting decreased Rasd2 expression in mice PFC, and RASD2 modulated dopamine D2 receptor (DRD2)-mediated antidepressant-like effects in ovariectomized mice. This research suggests the role of RASD2 in stress-induced depression and its underlying neural mechanisms that require further investigation. Here, we show that 5-day unpredictable mild stress (5-d UMS) exposure reduces RASD2 expression in both the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) of mice, while overexpression (but not knock-down) of Rasd2 in the NAc core (NAcc) alleviates 5-d UMS-induced depression-like behaviors and activates the DRD2-cAMP-PKA-DARPP-32 signaling pathway. Further studies investigated neuronal projections between the mPFC (Cg1, PrL, and IL) and NAcc, labeled by the retrograde tracer Fluorogold. Depression-like behaviors induced by 5-d UMS were only related to inhibition of the PrL-NAcc circuit. DREADD (Designer receptors exclusively activated by designer drug) analysis found that the activation of PrL-NAcc glutaminergic projection alleviated depression-like behaviors and increased DRD2- and RASD2-positive neurons in the NAcc. Using Drd2-cre transgenic mice, we constructed mice with Rasd2 overexpression in DRD2PrL-NAcc neurons, finding that Rasd2 overexpression ameliorated 5-d UMS-induced depression-like behaviors. These findings demonstrate a critical role for RASD2 modulation of DRD2PrL-NAcc neurons in 5-d UMS-induced depression-like behaviors. In addition, the study identifies a new potential strategy for precision medical treatment of depression.

Self-compassion and psychological mindedness in depressed Turkish adolescents with non-suicidal self-injury

ABSTRACT Objective Non-suicidal self-injury (NSSI) is a significant mental health issue among depressed adolescents. This study aimed to investigate roles of psychological mindedness (PM) and self-compassion among depressed Turkish adolescents with NSSI. The mediating roles of PM and self-compassion between depression severity and NSSI were evaluated. Method 119 depressed adolescents evaluated at a child psychiatry outpatient clinic in Turkey were categorised based on NSSI experience. Self-compassion and psychological mindedness scales (covering psychological interest, insight, help-seeking, and capacity for change subscales) were measured. Results PM and self-compassion scores were lower in depressed adolescents with NSSI than adolescents without NSSI. Psychological interest (Odds Ratio (OR): 0.886, Confidence Interval (CI): 0.788–0.996), capacity for change (OR: 0.902, CI: 0.815–0.998), and self-compassion (OR: 0.937, CI: 0.879–0.999) emerged as protective factors against NSSI. Also, significant indirect effects of PM and self-compassion were observed between depression severity and NSSI. Seeking psychological help related to both intrapersonal and interpersonal functions, whereas psychological interest specifically related to interpersonal functions. Conclusions PM and self-compassion appear as protective factors, with certain PM components linked to intrapersonal and interpersonal functions of NSSI. Thus, integrating interventions to boost PM and self-compassion into depression treatment strategies could be crucial.

Physiotherapy for patients with depression: Recent research progress.

Depression, a common mental illness, seriously affects the health of individuals and has deleterious effects on society. The prevention and treatment of depression has drawn the attention of many researchers and has become an important social issue. The treatment strategies for depression include drugs, psychotherapy, and physiotherapy. Drug therapy is ineffective in some patients and psychotherapy has treatment limitations. As a reliable adjuvant therapy, physiotherapy compensates for the shortcomings of drug and psychotherapy and effectively reduces the disease recurrence rate. Physiotherapy is more scientific and rigorous, its methods are diverse, and to a certain extent, provides more choices for the treatment of depression. Physiotherapy can relieve symptoms in many ways, such as by improving the levels of neurobiochemical molecules, inhibiting the inflammatory response, regulating the neuroendocrine system, and increasing neuroplasticity. Physiotherapy has biological effects similar to those of antidepressants and may produce a superimposed impact when combined with other treatments. This article summarizes the findings on the use of physiotherapy to treat patients with depression over the past five years. It also discusses several methods of physiotherapy for treating depression from the aspects of clinical effect, mechanism of action, and disadvantages, thereby serving as a reference for the in-depth development of physiotherapy research.

Gut bacteria-driven homovanillic acid alleviates depression by modulating synaptic integrity

The gut-brain axis is implicated in depression development, yet its underlying mechanism remains unclear. We observed depleted gut bacterial species, including Bifidobacterium longum and Roseburia intestinalis, and the neurotransmitter homovanillic acid (HVA) in individuals with depression and mouse depression models. Although R.intestinalis does not directly produce HVA, it enhances B.longum abundance, leading to HVA generation. This highlights a synergistic interaction among gut microbiota in regulating intestinal neurotransmitter production. Administering HVA, B.longum, or R.intestinalis to mouse models with chronic unpredictable mild stress (CUMS) and corticosterone (CORT)-induced depression significantly improved depressive symptoms. Mechanistically, HVA inhibited synaptic autophagic death by preventing excessive degradation of microtubule-associated protein 1 light chain 3 (LC3) and SQSTM1/p62 proteins, protecting hippocampal neurons' presynaptic membrane. These findings underscore the role of the gut microbial metabolism in modulating synaptic integrity and provide insights into potential novel treatment strategies for depression.

DNA methylation signatures support the role of neutrophils and monocytes in depression

IntroductionResearch repeatedly linked inflammation with major depressive disorder (MDD). The presence of an inflammatory subtype of depression is supported by molecular findings as well as imaging reports. We investigated the cell type composition estimated by using epigenome-wide DNA methylation markers in a sample of depressed individuals showing high or low inflammation levels measured by hsCRP. We aimed to understand the connection between depression and inflammation, specifically differences in cell type compositions between high and low inflammation groups at baseline.Objectives119 individuals with MDD were included for this analysis. Following quality control procedures, 113 participants were included in the analysis (Mage= 47 years, 57.98% women). The sample consisted of 37 individuals with high hsCRP (hsCRP &gt; 1.5, Mage=45, MhsCRP=8.2, MMADRS=28, 70% women) and 76 individuals with low hsCRP (hsCRP &lt; 1.5, Mage= 44, MhsCRP=0.99, MMADRS=28, 49% women).MethodsThe Illumina Infinium MethylationEPIC 850k BeadChip was used for analyzing whole blood derived DNA. Data processing and cell type estimation was conducted using the RnBeads package. We applied the Houseman method to estimate cell type composition through epigenome-wide DNA methylation signatures, resulting in six cell types: neutrophils, natural killer cells, B cells, CD4+ T cells, CD8+ T cells and monocytes. Comparisons between both groups were tested using ANOVA.ResultsHigh and low hsCRP groups were compared for each of the six cell types estimated. A statistically significant difference was seen for monocytes (p=0.0316) and a trend for neutrophils (p=0.0742). The mean values for neutrophils in patients without inflammation were found to be 60%, while in patients with inflammation, it was 63%. For monocytes, the mean values for patients without inflammation and those with inflammation were 10% and 9.4%, respectively, with a smaller range (4.5%-14.3%) for individuals with inflammation as compared to patients without inflammation (5.3%-20.7%). None of the other four cell types showed a statistically significant difference.Conclusions We identified differences in the cell type composition between groups of depressed patients with high versus low inflammation. These results align with the existing body of knowledge reported in established academic literature. Our study emphasizes the role of specific cells like neutrophils and monocytes in inflammation and depression. These findings offer valuable insights for improving depression treatment strategies as inflammation state may be relevant for treatment response. We also show the merit of DNA methylation signatures for the profiling of patients’ inflammation status, i.e., immunomethylomics.Disclosure of InterestNone Declared

Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.

Treatment strategies for depression based on interventions for glucose and lipid metabolism disorders are receiving increasing attention. Investigating the mechanism of their antidepressant effect and exploring new diagnostic and therapeutic biomarkers have attracted increasing attention. Dulaglutide, a long-acting GLP-1 receptor agonist, has been reported to alleviate cognitive deficits and neuronal damage. However, the antidepressant effect of dulaglutide and, especially, the underlying mechanism are still poorly understood. In this study, we aimed to explore the underlying biomarkers of depression and potential modulatory targets of dulaglutide in chronic mild stress (CMS) mice. Sixty mice were randomly divided into a control group (CON group), a CMS+Vehicle group (CMS+Veh group), a CMS+0.3mg/kg dulaglutide group (Low Dula group), and a CMS+0.6mg/kg dulaglutide group (High Dula group). Numerous behavioral tests, mainly the open field test, forced swimming test, and tail suspension test, were applied to evaluate the potential effect of dulaglutide treatment on anxiety- and depression-like behaviors in mice exposed to chronic stress. Furthermore, a liquid chromatography-tandem mass spectrometry-based metabolomics approach was utilized to investigate the associated mechanisms of dulaglutide treatment. Three weeks of dulaglutide treatment significantly reversed depressive-like but not anxiety-like behaviors in mice exposed to chronic stress for 4 weeks. The results from the metabolomics analysis showed that a total of 20 differentially expressed metabolites were identified between the CON and CMS+Veh groups, and 46 metabolites were selected between the CMS+Veh and High Dula groups in the hippocampus of the mice. Comprehensive analysis indicated that lipid metabolism, amino acid metabolism, energy metabolism, and tryptophan metabolism were disrupted in model mice that experienced depression and underwent dulaglutide therapy. The antidepressant effects of dulaglutide in a CMS depression model were confirmed. We identified 64 different metabolites and four major pathways associated with metabolic pathophysiological processes. These primary data provide a new perspective for understanding the antidepressant-like effects of dulaglutide and may facilitate the use of dulaglutide as a potential therapeutic strategy for depression.

Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines

Abstract: While the number of treatment options for major depressive disorder (MDD) has grown in recent years, the lack of quality data to guide optimal modality selection has lessened the potential impact of having a more diverse set of mechanistic approaches to treatment. The last attempt to investigate treatment sequencing for MDD was the Sequenced Treatment Alternatives for Relief of Depression Study (STAR*D), which gave rise to the concept of treatment-resistant depression (TRD) as a failure to respond to two or more monoaminergic antidepressants. However, a recent reanalysis of the STAR*D data indicates that most patients do not remit even when treated with multiple traditional antidepressants. Given these new results, labeling the majority of patients as treatmentresistant is not appropriate or useful. If monoamine-based drugs are not that effective for the majority of MDD patients, then it is necessary to consider the mechanistically distinct pharmacological and non-pharmacological treatment options that have emerged recently, including brain stimulation, glutamate receptor modulators, and psychedelic medicines. While these new treatment modalities have the potential to enhance patient outcomes, clinicians and patients currently lack a framework to guide their choices other than cost, feasibility, personal preference, and certain medical contraindications. Here, we review alternative treatment modalities for monoamine non-responders and consider the possibility that there will be new first-line therapies for MDD. We will review how treatment decisions for these patients are currently being made and how developments in precision psychiatry may help guide rational treatment selection in the future.

Aurantii fructus immaturus carbonisata-derived carbon dots and their anti-depression effect.

Introduction: Depression is a common illness worldwide. However, the current treatments available for depression only achieve relative success, often come with several side effects, and are associated with high costs. Aurantii Fructus Immaturus (AFI) has a rich historical legacy in Traditional Chinese Medicine (TCM) for its traditional use as a treatment for depression. In this research, our primary objective is to examine the potential antidepressant properties and the mechanisms at play behind a particular bioactive compound found in AFI, which is referred to as carbon dots derived from AFI Carbonisata (AFIC-CDs). Methods: Extracted and isolated the AFIC-CDs from the decoction of AFIC, then characterized the morphological structure and functional groups comprehensively. We then utilized two distinct models to investigate the anti-depressive properties of AFIC-CDs: the chronic unpredictable mild stress (CUMS) model and the reserpine-induced pain-depression dyad model. In the CUMS model, we assessed immobile time and measured neurotransmitter levels in the mouse brain cortex. In the pain-depression dyad model, we evaluated immobile time, neurotransmitter levels, interleukin-1 (IL-1β) and tumor necrosis factor-α (TNF-α) levels, and the expression of mRNA of brain-derived neurotrophic factor (BDNF) and tryptophan hydroxylase 2 (Tph2). Results: AFIC-CDs were found to have abundant chemical groups, and their diameter ranged from 2 to 10nm. In the CUMS model, AFIC-CDs demonstrated significant effects. They reduced the immobile time of the mice and increased the levels of serotonin (5-HT), dopamine (DA), and norepinephrine (NE) in the mouse brain cortex. In the pain-depression dyad model, the AFIC-CDs groups decreased the immobile time, showed effect in increasing both the neurotransmitters' levels and the expression of mRNA of BDNF and Tph2, and decreased the IL-1β and TNF-α levels in mouse brain cortex. Taken together, these results strongly indicate that AFIC-CDs possess significant antidepressant activity. Conclusion: AFIC-CDs demonstrate promising therapeutic potential in the treatment of depression, suggesting that they may become a valuable candidate for depression management. This not only extends the understanding of the biological activity of carbon dots (CDs) but also opens up new possibilities for the development of effective depression treatment strategies.

Depression in Polycystic Ovary Syndrome: Focusing on Pathogenesis and Treatment.

Polycystic ovary syndrome (PCOS) is one of the most prevalent gynecological endocrine conditions affecting reproductive women. It can feature a variety of symptoms, such as obesity, insulin resistance, skin conditions, and infertility. Women with PCOS are susceptible to illnesses including mood disorders, diabetes, hypertension, and dyslipidemia. Among them, depression is the most common in PCOS and has a detrimental effect on quality of life. Depression may occasionally develop due to the pathological traits of PCOS, but its exact pathogenesis in PCOS have eluded researchers to date. Therefore, there is an urgent need to explore the pathogenesis and treatments of depression in PCOS. The present review discusses the epidemiology of depression in PCOS, potential pathogenic mechanisms underlying PCOS and depression, as well as some potential factors causing depression in PCOS, including obesity, insulin resistance, hyperandrogenism, inflammation, and infertility. Meanwhile, some common treatment strategies for depression in PCOS, such as lifestyle intervention, acupuncture, oral contraceptive pills, psychological intervention, and insulin-sensitizer, are also reviewed. To fully understand the pathogenesis and treatment of depression in PCOS, a need remains for future large-scale multi-center randomized controlled trials and in-depth mechanism studies. Appeared originally in Front Psychiatry 2022; 13:1001484.

Treating Psychological Depression Utilising Artificial Intelligence: AI for Precision Medicine- Focus on Procedures

Depression is a common and complex mental health condition that affects millions of people in the world. Medical advice, medications, and constant medical supervision by a specialist are common components of traditional treatment methods. Recently, there has been a growing interest in the potential of artificial intelligence to improve the diagnosis, monitoring, and treatment of depression. The potential of artificial intelligence algorithms has been demonstrated in the development of chatbots, or virtual agents, that can provide treatment, assistance, and support to individuals with depression. These artificial intelligence (AI) systems can simulate therapy sessions, offer strategies, monitor progress in treatment phases, and speak in natural language. Artificial intelligence has the potential to play an important role in the early diagnosis and prognosis of depression. By analysing multiple data sets and information such as genetic information, patient medical records, and social media posts using the Internet, artificial intelligence algorithms can identify individuals vulnerable to depression and distinguish them from normal humans. This facilitates the implementation of interventions and preventive measures at the right time and day. AI can also be used to improve depression treatment strategies. By analysing massive databases of patient data, AI systems can determine the ideal drug combinations, doses, amounts, and combinations for each patient. This personalized approach can lead to better treatment outcomes and reduces the trial-and-error process typically required to determine the best action. While AI has the potential to treat psychological depression, it is important to keep in mind that AI should never replace qualified and helpful medical professionals. Artificial intelligence in treating depression seeks to enhance and support the care provided by therapists, psychologists, and psychiatrists, rather than replace human communication and knowledge.

Ketamine - A New Antidepressant Drug with Anti-Inflammatory Properties.

Ketamine is a new, potent and rapid-acting antidepressant approved for therapy of treatment-resistant depression, which has a different mechanism of action than currently-available antidepressant therapies. It owes its uniquely potent antidepressant properties to a complex mechanism of action, which currently remains unclear. However, it is thought that it acts by modulating the functioning of the glutamatergic system, which plays an important role in the process of neuroplasticity associated with depression. However, preclinical and clinical studies have also found ketamine to reduce inflammation, either directly or indirectly (by activating neuroprotective branches of the kynurenine pathway), among patients exhibiting higher levels of inflammation. Inflammation and immune system activation are believed to play key roles in the development and course of depression. Therefore, the present work examines the role of the antidepressant effect of ketamine and its anti-inflammatory properties in the treatment of depression. SIGNIFICANCE STATEMENT: The present work examines the relationship between the antidepressant effect of ketamine and its anti-inflammatory properties, and the resulting benefits in treatment-resistant depression (TRD). The antidepressant mechanism of ketamine remains unclear, and there is an urgent need to develop new therapeutic strategies for treatment of depression, particularly TRD.

Sex Differences in Prevalence and Clinical Correlates of Depression in Individuals Infected with Omicron in China.

Sex differences in depression have been well recognized. However, sex differences in depression among Omicron-infected individuals have received little systematic study. This study compared sex differences in depression in infected individuals during the 2022 Omicron pandemic in China. 506 individuals infected with Omicron (males/females = 268/238) were recruited from Tianjin and Shanghai in China. Self-developed Scale of Demographics were used to collect demographic and clinical data, Zung Self-Rating Depression Scale (SDS), Zung Self-Rating Anxiety Scale (SAS), the Connor-Davidson Resilience Scale (CD-RISC), De Jong Gierveld Scale (DJGLS), and the Penn State Worry Questionnaire (PSWQ) were used to measure respondents' depression, anxiety, resilience, loneliness and worry, respectively. The prevalence rate of depression in male patients was significantly higher than in female patients (42.2% versus 31.9%; χ2 = 5.64, p = 0.018). Regression analysis showed that in female patients, depression was associated with anxiety [OR = 1.26, 95% CI (1.16-1.36), p < 0.001], and resilience [OR = 0.98, 95% CI (0.96-1.00), p < 0.05], while in male patients, depression was associated with anxiety [OR = 1.24, 95% CI (1.15-1.33), p < 0.001]. This on-site study demonstrates that depression is more frequent in male than female Omicron-infected patients and suggests that sex differences should be considered in prevention and treatment strategies for depression during the Omicron pandemic.

Targeting Mitochondrial Homeostasis: The Role of Acupuncture in Depression Treatment.

Depression is a common mental health disorder characterized by persistent feelings of sadness, loss of interest or pleasure, and a range of physical and cognitive symptoms. It affects people of all ages and can significantly impact their daily functioning and quality of life. Mitochondrial homeostasis plays an important role in the pathogenesis of depression. Mitochondrial homeostasis includes mitophagy, mitochondrial oxidative stress, mitoptosis, mitochondrial biogenesis, and mitochondrial dynamics. The regulation of mitochondrial homeostasis is the key link in the prevention and treatment of depression. In this article, we focus on the core link of depression-mitochondrial homeostasis and summarize the research progress of acupuncture targeting mitochondrial homeostasis in the treatment of depression in recent years, so as to provide ideas and experimental basis for the research and formulation of more appropriate depression treatment strategies. Acupuncture has been found to regulate mitochondrial homeostasis (by modulating mitochondrial autophagy, reducing mitochondrial oxidative stress, inhibiting mitochondrial fission, inducing mitochondrial biogenesis, and maintaining mitochondrial dynamics), alleviate depression-like behavior, and regulate signal pathways and key proteins. Here, we highlight the role of acupuncture in the treatment of depression. A comprehensive exploration of the impact of acupuncture on mitochondrial homeostasis could potentially present a novel mechanism for treating depression and offer fresh perspectives for the treatment of patients with clinical depression.

Effects of Music, Massage, Exercise, or Acupuncture in the Treatment of Depression Among College Students: A Network Meta-Analysis.

To assess the therapeutic impacts of exercise, massage, and music interventions on college students experiencing depression by employing a mesh meta-analysis approach. This research intends to offer valuable insights to aid in the development of non-pharmaceutical treatment strategies for depression. We conducted a thorough search across various databases including Cochrane, PubMed, Embase, Web of Science, CNKI, and Wanfang to explore the effects of music, massage, aerobic exercise, fitness Qigong, yoga, tai chi, ball games, strength training, dance, whole body vibration training, and high-intensity interval training on the treatment of depression in college students. The search period was from January 1, 2023, which marks the establishment of each database. Subsequently, a mesh meta-analysis was performed using the "Stata 15.1" software, incorporating outcome indicators from 24 included literature comprising a total of 1458 patients. Based on the ranking of the optimal intervention effects of various non-pharmaceutical methods, the order, from highest to lowest probability, was as follows: high-intensity interval training (96%), yoga (94.90%), dance (78.30%), music (73.30%), ball games (62.50%), strength training (51.70%), aerobic training (45.30%), tai chi (35.40%), vibration training (27.30%), massage (20.10%), qigong (14.30%), and no intervention (1.00%). This ranking aligns closely with the findings obtained from pairwise comparisons between different interventions. High-intensity interval training is likely to yield the most effective therapeutic results for college students with depression. In the pairwise comparison of different interventions, High-intensity interval training is also better than most interventions. However, to establish its intervention effect more conclusively, further validation through additional high-quality randomized controlled trials is necessary.

The impact of depressive symptomology, rumination and objective memory performance on subjective cognitive complaints

IntroductionCognitive impairment in depression can present as subjective or objective, but the intensity of the former is higher and is not correlated with the deficits measured in neuropsychological tests. We hypothesised that rumination would be associated with subjective cognitive impairment. MethodsThe study was performed through the online PsyToolkit platform. It included 168 healthy people and 93 people with depression. To examine memory, a recognition-type task was used with emotionally charged words as the stimulus. Depression symptoms were measured using the Beck Depression Inventory-II, subjective cognitive impairment with the Perceived Deficits Questionnaire-20, and intensity of rumination with the Polish Questionnaire of Rumination. ResultsMDD patients had significantly higher levels of depression symptoms, rumination, and subjective cognitive deficits than the control group. In the memory task, the MDD group had a higher error rate than the control group. In hierarchical regression analysis, depression and rumination were found to be significant predictors of subjective cognitive impairment, whereas objective memory performance was not. Exploratory analyses revealed that rumination mediates the association between depression and subjective cognitive complaints. ConclusionCognitive problems are common in depression and affect the quality of life. The results suggest that patients with depression have higher levels of rumination and subjective memory impairment, and that there is no direct link between subjective and objective cognitive decline. The findings may have implications for the development of effective treatment strategies for depression and cognitive impairment.

Influences of inattention on perceived self-efficacy, stress, and depression

IntroductionGoing through life mindlessly appears to produce feelings of boredom and depression, suggesting that cognitive deficits can lead both directly and indirectly to emotional problems. Under this hypothesis, there are numerous possible routes from attention to affective issues, including through the sense of self-efficacy – a judgement about our ability to successfully achieve goals – and the experience of psychological stress. The present study assessed potential pathways from everyday inattentiveness, through the presumed intermediate experiences of diminished self-efficacy and psychological stress, to the experience of depressive affect.MethodIn two studies we collected questionnaire responses from large groups of participants (N = 188, Study 1; N = 399, Study 2), assessing individual differences in trait inattention, attention-related errors, self-efficacy, stress, and depression.ResultsVia path analyses we tested several predictions: 1) the frequency of attention lapses predicts depressive affect; 2) attention-related errors mediate effects of inattention in predicting both self-efficacy and stress; 3) self-efficacy and stress directly influence depressive affect. The results indicate the proposed Attention-to-Affect models provide good fit overall. They also indicate a reversal of the causal flow, while consistent with traditional views, does not adequately fit the data.DiscussionThat the Attention-to-Affect models provide good fit for the data is consistent with the view that everyday inattention contributes to the emotional distress that creates depression. While this view is contrary to the typical conception of attention problems as consequences of depression, it is consistent with our own previous findings. Accordingly, our results continue to suggest it is important for future research to further validate this pathway and to consider directly remedying attentional issues as a potentially important part of depression treatment strategies.

Involvement of the serotonergic system in the antidepressant-like effect of 1-(phenylselanyl)-2-(p-tolyl)indolizine in mice

Depression is a mental disorder that affects approximately 280 million people worldwide. In the search for new treatments for mood disorders, compounds containing selenium and indolizine derivatives show promising results. To evaluate the antidepressant-like effect of 1-(phenylselanyl)-2-(p-tolyl)indolizine (MeSeI) (0.5-50mg/kg, intragastric-i.g.) on the tail suspension test (TST) and the forced swim test (FST) in adult male Swiss mice and to elucidate the role of the serotonergic system in this effect through pharmacological and in silico approaches, as well to evaluate acute oral toxicity at a high dose (300mg/kg). MeSeI administered 30min before the FST and the TST reduced immobility time at doses from 1mg/kg and at 50mg/kg and increased the latency time for the first episode of immobility, demonstrating an antidepressant-like effect. In the open field test (OFT), MeSeI did not change the locomotor activity. The antidepressant-like effect of MeSeI (50mg/kg, i.g.) was prevented by the pre-treatment with p-chlorophenylalanine (p-CPA), a selective tryptophan hydroxylase inhibitor (100mg/kg, intraperitoneally-i.p. for 4days), with ketanserin, a 5-HT2A/2C receptor antagonist (1mg/kg, i.p.), and with GR113808, a 5-HT4 receptor antagonist (0.1mg/kg, i.p.), but not with WAY100635, a selective 5-HT1A receptor antagonist (0.1mg/kg, subcutaneous-s.c.) and ondansetron, a 5-HT3 receptor antagonist (1mg/kg, i.p.). MeSeI showed a binding affinity with 5-HT2A, 5 -HT2C, and 5-HT4 receptors by molecular docking. MeSeI (300mg/kg, i.g.) demonstrated low potential to cause acute toxicity in adult female Swiss mice. In summary, MeSeI exhibits an antidepressant-like effect mediated by the serotonergic system and could be considered for the development of new treatment strategies for depression.